|
|
|
|
|
|
|
||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | ||||
DEVELOPMENT AND DISEASE |
1 Division of Mammalian Development,
2 Division of Protein Structure, National Institute for Medical Research, The Ridgeway, London NW7 1AA, UK
3 Institute of Child Health, 30 Guilford Street, London WC1N 1EH, UK
4 Department of Paediatric Endocrinology, John Radcliffe Hospital, Headley Way, Headington, Oxford OX3 9DU, UK
* Present address: Centre for Genome Research, The University of Edinburgh, Kings Buildings, West Mains Road, Edinburgh EH9 3JQ, UK
Authors for correspondence (e-mail: Josh.Brickman{at}ed.ac.uk and M.Dattani{at}ich.ucl.ac.uk)
Accepted October 10, 2001
The homeobox gene Hesx1/HESX1 has been implicated in the establishment of anterior pattern in the central nervous system (CNS) in a number of vertebrate species. Its role in pituitary development has been documented through loss-of-function studies in the mouse. A homozygous missense point mutation resulting in a single amino acid substitution, Arg160Cys (R160C), is associated with a heritable form of the human condition of septo-optic dysplasia (SOD). We have examined the phenotype of affected members in this pedigree in more detail and demonstrate for the first time a genetic basis for midline defects associated with an undescended or ectopic posterior pituitary. A similar structural pituitary abnormality was observed in a second patient heterozygous for another mutation in HESX1, Ser170Leu (S170L). Association of S170L with a pituitary phenotype may be a direct consequence of the HESX1 mutation since S170L is also associated with a dominant familial form of pituitary disease. However, a third mutation in HESX1, Asn125Ser (N125S), occurs at a high frequency in the Afro-Caribbean population and may therefore reflect a population-specific polymorphism. To investigate the molecular basis for these clinical phenotypes, we have examined the impact of these mutations on the regulatory functions of HESX1. We show that Hesx1 is a promoter-specific transcriptional repressor with a minimal 36 amino acid repression domain which can mediate promoter-specific repression by suppressing the activity of homeodomain-containing activator proteins. Mutations in HESX1 associated with pituitary disease appear to modulate the DNA-binding affinity of HESX1 rather than its transcriptional activity. Wild-type HESX1 binds a dimeric homeodomain site with high affinity (Kd 31 nM) whilst HESX1(S170L) binds with a 5-fold lower activity (Kd 150 nM) and HESX1(R160C) does not bind at all. Although HESX1(R160C) has only been shown to be associated with the SOD phenotype in children homozygous for the mutation, HESX1(R160C) can inhibit DNA binding by wild-type HESX1 both in vitro and in vivo in cell culture. This dominant negative activity of HESX1(R160C) is mediated by the Hesx1 repression domain, supporting the idea that the repression domain is implicated in interactions between homeodomain proteins. Our data suggest a possible molecular paradigm for the dominant inheritance observed in some pituitary disorders.
Key words: Repression, Homeodomain, Pituitary, Hesx1/HESX1, Transcription
This article has been cited by other articles:
|
|
 |
|
  A. Rajab, D. Kelberman, S. C.P. de Castro, H. Biebermann, H. Shaikh, K. Pearce, C. M. Hall, G. Shaikh, D. Gerrelli, A. Grueters, et al. Novel mutations in LHX3 are associated with hypopituitarism and sensorineural hearing loss Hum. Mol. Genet., July 15, 2008; 17(14): 2150 - 2159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Mitchell, P. Q. Thomas, M. R. Zacharin, and I. E. Scheffer Ectopic Posterior Pituitary Lobe and Periventricular Heterotopia: Cerebral Malformations with the Same Underlying Mechanism? AJNR Am. J. Neuroradiol., October 1, 2002; 23(9): 1475 - 1481. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. E. Olson and M. G. Rosenfeld Perspective: Genetic and Genomic Approaches in Elucidating Mechanisms of Pituitary Development Endocrinology, June 1, 2002; 143(6): 2007 - 2011. [Abstract] [Full Text] [PDF]
|
|
